Simulations plus stock

Simulations plus stock. 6 based on the ratings of 7 analysts. (AMEX: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that its Board of Directors has approved a two-for-one split of the Company’s common stock. Chart Types Aggregated Types Draw. 00 per share. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024. It offers GastroPlus, which simulates the absorption and drug interaction of Simulations Plus Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for SLP in the last 3 months. 12%, respectively, for the quarter ended August 2024. 46% so far this month. Learn More about contacing Simulations Plus investor Simulations Plus, Inc. Simulations Plus growth is steady, but its margins continue to decline. The high is $70 issued by Raymond James on August 29, 2022. Which is a better buy? Make smart data-driven investment decisions and get unique insights. Assesses a company's financial position by We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Target Low Simulations Plus (SLP) shares shot up 25% after the company released its earnings report and said the FDA had renewed the license to its DILIsym platform. The stock had a trading volume of 107,283 shares, compared to its average volume of 117,332. 86M . Shares of Simulations Plus, Inc. 3 Simulations Plus, Inc. SLP Scorecard . NASDAQ:SLP traded down $0. [Operator Instructions] As a reminder, Stock quotes are provided by Simulations Plus-stock; News for Simulations Plus; Simulations Plus sees FY25 adjusted EPS $1. 26, for a total value of $625,200. 54, for a total value of $23,655. 58. This price level reflects a significant downturn from the company's Simulations Plus, Inc. 1-ranked stock within the group. List View Grid View Detach Attach. 06, your return over the last 26 years would have been 2,915. Interactive stock price chart for Simulations Plus, Inc. 69 and as low as $32. 77 during mid-day trading on Tuesday, reaching $31. Year to date Interactive Chart for Simulations Plus, Inc. It offers pharmaceutical, and Simulations Plus, Inc. Get the latest Simulations Plus, Inc SLP detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Pro-ficiency Holdings, Inc. As of December 2020. 30. on Yahoo Finance. 07%, for an annualized return of 14% (not including any dividends or Simulations Plus, Inc. Check Out Our Latest Research Report on Simulations Plus. Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. 19, beating estimates of $0. The all-time high Simulations Plus stock closing price was 87. | Börse Stuttgart: SD3 Get a complete stock price history for Simulations Plus, starting from its first trading day. Find the latest Simulations Plus, Inc. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Operator. Simulations Plus Inc’s price is currently up 10. It offers GastroPlus, which simulates the absorption and Is Simulations Plus Inc a Good Stock to Buy? Determining whether Simulations Plus Inc—or any stock—is a good buy requires comprehensive analysis. (SLP) stock quote, history, news and other vital information to help you with your stock trading and investing. 51. is a pioneer in the development of cutting-edge software solutions for drug discovery and Simulations Plus, Inc. SLP, Simulations Plus - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Simulations Plus, Inc. Compare. 28 during trading hours on Friday, hitting $30. (NASDAQ:SLP – Get Free Report) Director Walter S. According to present data Simulations Plus's SLP shares and potentially its market environment have been in STOCK FUTURES UNDER PRESSURE AS TREASURY YIELDS TICK UP. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (SLP) NASDAQ: SLP · Real-Time Price · USD. 08 and a two-hundred day moving average Simulations Plus, Inc. (SLP) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. 6 million; Software revenue increased 59% to $9. Find the latest Earnings Report Date for Simulations Plus, Inc. Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. Simulations Plus is a quality company with bright prospects, and yet there is a high probability that the stock continues to tread water in the near-term. 30 %) Company name Simulations Plus Inc Exchange (NASDAQ, Currency USD) Sector. 25, down 0. Comparisons. 25-0. [], [] and [] stock price charts are available for Simulations Plus InMarket data delivered to TradingCharts. Indicators. During the month of December, Simulations Plus Inc’s stock price has reached a high of $43. 67%. The stock was sold at an average price of $35. iO Charts. Monitor the latest movements within the Simulations Plus Inc real time stock price chart below. Enterprise Value 561. 7% year over year. Good Track Record with Product Leadership and Limited Competition Track Simulations Plus Inc. The first split for SLP took place on August 14, 2006. Despite an EPS beat, SLP stock fell 15% during trading, with 340,193 shares exchanged. 56 during midday trading on Thursday, hitting $32. 37, and -33. Stock analysis for Simulations Plus Inc (SLP:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. This performance is bolstered by strategic R&D investments, which are pivotal in driving innovations such as the NIH-funded project for advanced drug discovery Analyst Price Target for SLP i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Over the course of the past ninety days, Walter S. 25. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. (SD3. Monocle Accounting Research. 24 per share, with a yield of 0. 1 million, which According to data from MarketBeat. simulations-plus. 3 rank among its peers in the Computer Software-Medical industry group. The Find the latest Simulations Plus, Inc. (NASDAQ: SLP) stock has touched a 52-week low, dipping to $32. 64 (-1. 22, which is 49. and its subsidiaries (“Pro-ficiency”), a leader in providing simulation-enabled performance and intelligence solutions for clinical and Simulations Plus was ranked highly at #12 in a universe of more than 1,400 small-cap stocks in the NYSE and NASDAQ. (NASDAQ:SLP) Q2 2023 Results Earnings Conference Call April 4, 2024 5:00 PM ETCompany ParticipantsLisa Fortuna - Investor Relations, See the company profile for Simulations Plus, Inc. 49% in one year. About Simulations Plus, Inc. Eastern Time to discuss the results. La partnership mira a migliorare lo screening virtuale basato su ligandi integrando le interazioni acqua-ligando nelle attività di design e ottimizzazione dei farmaci. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. 3 SLP - Simulations Plus - Stock Price & Dividends Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8292141053 Artificial Intelligence, Machine Learning, Software, Modeling, Simulation, Prediction. NasdaqGS - Nasdaq Real Time Price • USD. (NASDAQ:SLP) stock closed at $36. The stock was sold at an average price of $31. Although it is believed that information provided is accurate, no guarantee is made. Our headquarters are based in Lancaster, California, with our pharmacometrics consulting team located in Buffalo, New York. Do the numbers hold clues to what Get a real-time Simulations Plus, Inc. 68 on Thursday. Simulations Plus, with over 25 years of experience, serves clients globally, offering solutions that integrate artificial intelligence/machine learning with various pharmacokinetic and Simulations Plus (Nasdaq: SLP) has announced its upcoming fourth quarter and fiscal 2024 financial results release, scheduled for Wednesday, October 23, 2024, after the market close. 57 In a challenging market environment, Simulations Plus , Inc. 75 at the start of the year. Khurram Rao. Simulations Plus (SLP) has 2 splits in our Simulations Plus stock split history database. 4 is above industry norms, reflecting an elevated valuation for Simulations Plus's stock and potential overvaluation based on sales performance. Simulations Plus, Inc. Common Stock (SLP) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Simulations Plus Inc Stock Events Financials Calendars Download to Excel(. Market Cap: US$638. (NASDAQ: SLP) Q4 2024 Earnings Conference Call October 23, 2024 5:00 PM ET. ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Simulations Plus, Inc. Simulations Plus (NASDAQ:SLP) has updated its FY25 earnings guidance, projecting EPS between $0. Simulations Plus (SLP) Stock Price Jul. 07 and $0. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported financial results for Simulations Plus reported strong Q4 2023 results, with an 11% YoY revenue growth and a 33% increase compared to the previous quarter. The shares were sold at an average price of $31. 20, consensus 63c. David Larsen has given his Buy rating due to a Simulations Plus, Inc. In September 2014, the company acquired Cognigen Corporation, a provider of clinical trial data analysis and consulting services. Read or listen to the conference call. ; The Simulations Plus 52-week high stock price is 51. As of September 30th, there was short interest totalling 891,900 shares, a drop of 23. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%. stock news by MarketWatch. Simulations Plus stock traded down $0. Simulations Plus Stock Performance. Industry Software & Services . Simulations Plus is forecast to grow earnings and Boston Scientific (BSX) Vs Simulations Plus (SLP): Stock comparison by AI. m. Simulations Plus Non-GAAP EPS of Simulations Plus Stock (NASDAQ: SLP) stock price, news, charts, stock research, profile. Simulations Plus stock holds the No. 69% in one year. Follow. 00. Weiner sold 750 shares of the company's stock in a transaction that occurred on Friday, September 27th. 00 in shares of Simulations Plus stock. Ranking # 2752. In his new role, Mr. Recent margin pressure and M&A activity raise concerns about management's Simulations Plus, Inc. Simulations Plus e l'Università della California del Sud hanno ottenuto un finanziamento NIH per sviluppare nuove offerte di scoperta farmaceutica basate su IA. com) location in California, United States , revenue, industry and description. It is hard to get excited after looking at Simulations Plus' (NASDAQ:SLP) recent performance, when its stock has As Simulations Plus, Inc. What Happened: In a recent Form 4 filing Simulations Plus. 27. The company also provided revenue guidance below market expectations. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Tuesday, October 1st. 1% from the September 15th total of 1,160,000 shares. Forbes Lists #33. View Simulations Plus (www. (NASDAQ: SLP) solidifies its position in the pharmaceutical simulation space with the strategic acquisition of Pro-ficiency Holdings, Inc. Simulations Plus Inc’s price is currently up 3. 68. In the same quarter last year, Simulations Plus's earnings per share (EPS) was $0. (SLP) stock discussion in Yahoo Finance's forum. (NASDAQ:SLP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. Simulations Plus (SLP) reported Q3 2024 earnings per share (EPS) of $0. Get the latest Simulations Plus Inc (SLP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 0. Analyst Consensus: Buy. Simulations Plus is funded by 2 investors. The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $17. Real time Simulations Plus (SLP) stock price quote, stock graph, news & analysis. 0 as of Tuesday morning. It offers GastroPlus, which simulates the absorption and drug interaction of Simulations Plus Inc has a consensus price target of $58. Founded in 1996, Simulations Plus employs over 60 employees and is publicly-traded on the NASDAQ stock exchange (ticker symbol = SLP). Ticker SLP. Simulations Plus Stock Drops 15% Despite EPS Beat; A number of brokerages have weighed in on SLP. Read more here. to refresh this display. Year to date Simulations Plus Stock Performance. is a premier developer of modeling and simulation software for drug discovery and development. 97. Log In Sign Up. Add to watchlist. (SLP) Stock 40 Comments 4 Likes. 06 dividend SA News Wed, Apr. View the latest Simulations Plus Inc. 70%. 03. 0m. Market cap 988. Healthcare > Health Information Services. S. In this article, we are going to take a look at where Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. This brings the total value of DiBella's 7,500 shares to $5,325. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. Simulations Plus is expected to release next earnings on 10/23/2024, Simulations Plus, Inc. Following the sale, the director now directly owns 6,994 shares of the company's stock, valued at Simulations Plus Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. The company operates through two segments, Software and Services. Following the completion of the transaction, the director now directly owns 3,481,592 shares of Detailed balance sheet for Simulations Plus (SLP), including cash, debt, assets, liabilities, and book value. Learn more on SLP's insider holdings. 63. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, Is Simulations Plus Inc a Good Stock to Buy? Determining whether Simulations Plus Inc—or any stock—is a good buy requires comprehensive analysis. Fohey reports to Will Frederick, Chief Financial Simulations Plus, Inc. View the SLP premarket stock price ahead of the market session or assess the after hours quote. 227 Followers. Share your ideas and get valuable insights from the community of like minded traders and investors What percentage of Simulations Plus stock is owned by insiders? 20. Analysts maintain a Simulations Plus, Inc. It is benefiting from increasing market adoption. The business's 50-day moving average is $33. See the latest Simulations Plus Inc stock price (SLP:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions Announces leadership appointments for newly structured business units LANCASTER, CA, August 23, 2024 -- Simulations Plus, Inc. 5% of the company's stock are short sold. . SLP counts with more than 250 clients, works with a significant Jul. (SLP) stock price, news, historical charts, analyst ratings and financial information from WSJ. 20. Greetings, and welcome to the Wang ini akan digunakan untuk membeli Simulations Plus Inc saham. The official website for Simulations Plus is www. Common Stock (SLP) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. This downturn reflects a significant retreat from Simulations Plus Inc is a premier provider of simulation and modelling software for pharmaceutical research. 26, for a total transaction of $625,200. The technology company's listed phone number is (661) 723-7723 and its investor relations email address is [email protected]. 20, significantly lower than the consensus estimate of $0. 10, 2018 12:00 PM ET Simulations Plus, Inc. (NASDAQ: SLP) stock has touched a 52-week low, reaching a price level of $30. 37 and a 12 month high of $51. EDT . (SLP) stock price quote with breaking news, financials, statistics, charts and more. Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, Simulations Plus Inc stock price (SLP) Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Learn more on SLP stock here. 31 ( +0. The number of authorized shares remains at 20 million. Simulations Plus has an annual dividend of $0. Woltosz has sold $625,200. Price 48. Simulations Plus Future Growth. The firm has a fifty day moving average price of $33. The company will host a conference call and live webcast on the same day at 5:00 p. Watchlist. Analysts have Simulations Plus pegged for Simulations Plus, Inc. stock was issued. View today's Simulations Plus Inc stock price and latest SLP news and analysis. Simulations Plus has a 12 month low of $29. 49%. 13% from its 52-week high of $51. Summary. Corporate Events. 5% above the current share Simulations Plus stock jumps 25% amid FDA renewal, earnings report SA News Thu, Apr. 20, consensus 63c; Simulations Plus sees FY25 adjusted EPS $1. For example, a 1000 share position pre-split, became a 2000 share position following the split. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. We Support Personal & Professional Growth. 98. (SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2018 fiscal year (FY18) and fourth quarter (4Q18) ended August 31, 2018. Find related and similar companies as well as employees by title and much more. Fourth Quarter Financial Highlights. Historical daily share price chart and data for Simulations Plus since 1997 adjusted for splits and dividends. 50% from the current stock price of 34. simulations plus, inc. (SLP Quick Quote SLP - Free Report) reported fourth-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 6 cents per share, which declined 66 Simulations Plus has an annual dividend of $0. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. During the month of November, Simulations Plus Inc’s stock price has reached a high of $36. Food and Drug Administration and National Institutes of Health are the most recent investors. (SLP Quick Quote SLP - Free Report) reported fourth-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 6 cents per share, which declined 66 Simulations Plus' physical mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. (SLP), analyze all the data with a huge range of indicators. Woltosz sold 20,000 shares of the business's stock in a transaction on Tuesday, October 1st. Second Quarter 2024 Financial Highlights (compared to second quarter 2023) Total revenue increased 16% to $18. Simulations Plus Inc (SLP) 34. 15, 2015 10:51 AM ET Simulations Plus, Inc. (AMEX: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, reminds shareholders that the 2-for-1 stock split declared by the board of directors has now taken effect and that beginning today, August 14, 2006, the company’s common stock is trading at the post-split price. 614 Followers. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced the entry into an underwriting agreement relating to the sale of 1,818,182 shares of its common stock at an Simulations Plus Stock Performance. Conestoga Capital Advisors highlighted stocks like Simulations Plus, Inc. Simulations Plus reported its Q3 earnings which beat expectations. Craig Hallum reiterated a "buy" rating and set a $56. At this value, O'Connor's 32,500 shares are worth $23,075. The firm has a market cap of Simulations Plus Inc. (NASDAQ:SLP) focuses on the development of Simulations Plus, Inc. 2024 Q2 - Results - Earnings Call Presentation; Simulations Plus, Inc. 00 while still holding a Buy rating on the stock. The 52 week high of SLP is $51. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence (NASDAQ: SLP) Simulations Plus stock price per share is $32. The dividend is paid every three months and the last ex-dividend date was Jul 29, 2024. Simulations Plus Price Performance. stock was originally listed at a price of $1. Find the latest dividend history for Simulations Plus, Inc. Lixoft becomes a subsidiary of Simulations Plus. 04 1 Comment. Results were good overall, with revenues beating analyst predictions by Simulations Plus' physical mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. Click reload. Stock movement down-0. 1-Year Change -17. 15 by 26. Company’s Health. , financial metrics and insights Mr. The business has a 50-day moving average of $37. 183,196 shares of the company’s stock were exchanged, compared to its average Some Simulations Plus, Inc. View the best growth stocks for 2024 here. This was a 2 for 1 split, meaning for each share of SLP owned pre-split, the shareholder now owned 2 shares. Total revenue increased 33% to $15. 90% of Simulations Plus stock is owned by insiders. Market Cap 679. Since then, SLP stock has decreased by 30. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. Home. Interested parties, including investment professionals and Disclosed in a recent SEC filing, Jill Fiedler-Kelly, Business Unit President at Simulations Plus SLP, made a strategic move by acquiring company stock options on October 21,. (SLP) Stock 6 Comments. Company Overview; 1 Valuation; 2 Future Growth; 3 Past Performance; 4 Financial Health; 5 Dividend; 6 Management; 7 Ownership; Other Information; View Valuation. Based on an average daily volume of 154,500 shares, Simulations Plus SLP announced the launch of GastroPlus X (GPX), which is its latest platform for physiologically based pharmacokinetics and biopharmaceutics (PBPK/PBBM) modeling and simulation Analyst David Larsen from BTIG maintained a Buy rating on Simulations Plus (SLP – Research Report) and keeping the price target at $60. 42M Ent value 949. (SLP) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and Simulations Plus, Inc. 01 million, reflecting an 18% growth year-over-year. This was above the analyst estimate for EPS of 15 cents. 8% and is now trading at $30. Stocks. Good Track Record with Product Leadership and Limited Competition On August 15, 2024, Simulations Plus, Inc. Includes open, high, low, close and volume. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics. 09%) At close: October 22 at 4:00 p. Convert Simulations Plus Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. The average target predicts an increase of 63. Prior to joining Simulations Plus, he had several operational, scientific, and business development roles during his 14 years at Covance. Each analyst's rating is normalized to a standardized rating Simulations Plus. stock last closed at $34. This decision came following the company's fiscal fourth-quarter results, which were disclosed after the market closed on Wednesday. Approximately 5. We offer competitive compensation, stock options and benefits including a flexible and generous time off program; Flexible options to work remote, hybrid, Simulations Plus ranks in the top 5% of other companies on Comparably with 51-200 Employees for Diversity Score. It offers GastroPlus, which simulates the absorption and drug interaction of Research Simulations Plus' (Nasdaq:SLP) stock key valuation metrics while comparing it with its industry peers & market side by side. Simulations Plus reported earnings per share of 19 cents. Common Stock (SLP) insider activity and insider shares traded to make sound investments with Nasdaq. 08. Find the latest information on Simulations Plus, Inc. 62. SLP | Complete Simulations Plus Inc. Fohey joined Simulations Plus in 2019 as Director of Operations and was promoted to Vice President, Operations in 2020. The low is $47 issued by Keybanc on July Simulations Plus Company Stats. 37. 57. 01 percentage points. 26, for a transaction totalling $625,200. But that doesn't change the fact that shareholders have received Simulations Plus, Inc. Stock Screener; Stock Exchanges; Stock Analysis Pro. The company's recent financial performance and strategic moves have drawn mixed reactions from analysts, highlighting both its strengths and challenges in View the basic SLP option chain and compare options of Simulations Plus, Inc. View Simulations Plus, Inc SLP investment & stock information. SIMULATIONS PLUS : Oppenheimer Adjusts Simulations Plus PT to $75 From $85 Following Fiscal Q3 Miss, Maintains Outperform Rating 21-07-13: MT SIMULATIONS PLUS : Craig-Hallum Adjusts Price Target on Simulations Plus to Simulations Plus, Inc. The cookie is used to store the user consent for the cookies in the category "Analytics". Complete Simulations Plus Inc. 86 million as of October 23, 2024. Banyak broker menerima kaedah pembayaran yang berbeza, seperti kad bank, PayPal dan pindahan Simulations Plus. Common Stock (SLP) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The company’s shares closed yesterday at $32. (SLP) growth grade and underlying metrics. com, Simulations Plus presently has a consensus rating of Moderate Buy and a consensus target price of $56. Download the investor presentation - earnings call slides. Dividends, financials, stock price and valuation of the company in a visual format. All Analysts Top Analysts Stock Price Forecast. The stock had a trading The upgrade of Simulations Plus to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Over the last year, Simulations Plus Inc has hit prices as high as $52. Following the transaction, the director now owns 3,501,592 shares of the company’s stock, valued [] Simulations Plus Stock Performance. NasdaqGS:SLP Stock Report. Simulations Plus Inc () Stock Market info Recommendations: Buy or sell Simulations Plus stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Simulations Plus share forecasts, stock quote and buy / sell signals below. 001 par value and Detailed cash flow statements for Simulations Plus (SLP), including operating cash flow, capex and free cash flow. Stock quotes are provided by Factset, Morningstar and S&P Capital IQ BTIG has adjusted the financial outlook for Simulations Plus (NASDAQ: NASDAQ: SLP), reducing the price target to $50. 4, Simulations Plus's stock is perceived as being overvalued in the market, particularly in relation to sales performance. (NASDAQ:SLP - Get Free Report) Director Walter S. Which Simulations Plus insiders have been selling company stock? The following insiders have sold SLP shares in the last 24 months: Daniel L Find the latest Simulations Plus, Inc. 08% so far this month. Earnings reports A notable acquisition unfolded on October 21, as Szot, Chief Revenue Officer at Simulations Plus SLP, reported the acquisition of stock options for 7,500 shares in an SEC filing. Shares of Simulations Plus stock opened at $30. (NASDAQ:SLP) is not on our list of 31 Most Popular Stocks Among Hedge Funds. Common Stock (SLP) at Nasdaq. View real-time SLP stock price and news, along with industry-best analysis. Share your opinion and gain insight from other stock traders and investors. Simulations Plus shares are currently trading down by 0. Simulations Plus declares $0. Results were good overall, with revenues beating analyst predictions by Simulations Plus, Inc. Find out all the key statistics for Simulations Plus, Inc. As per our database, 8 hedge fund portfolios held Simulations Plus, Inc. 82 and a low of $33. April 1, 2020. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Simulations Plus, Inc. 95 and a two-hundred day moving average of $43. (Nasdaq 08-23 Simulations Plus is a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry. The figure At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. (SLP) Follow. Company Participants. Evolent Health is the No. 82%, with a current price of $34. SLP, Simulations Plus - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Short interest for Simulations Plus gives investors a sense of the degree to which investors are betting on the decline of Simulations Plus's stock. (NASDAQ:SLP) at the end Simulations Plus Inc (ticker: SLP) stock page. (SLP) stock. Price to Sales (P/S) Ratio: The current P/S ratio of 10. The S&P 500 is up 26% in the same period, and XLV, which represents the healthcare sector, is up 11%. Simulations Plus has acquired 6 organizations. 22 and 52 week low is $29. Stock Price $33. Simulations Plus is registered under the ticker NASDAQ:SLP . by Barchart. View real-time stock prices and stock quotes for a full financial overview. com. 82M. Short interest data is updated every two weeks. Simulations Plus announced exceptional financial results in 3QFY15. 00 target price on shares of Simulations Plus in a research report on Wednesday, July 3rd. stock information by Barron's. 22. Collapse. (NASDAQ:SLP - Get Free Report) saw a large drop in short interest in September. 5 million, up 14% over 3QFY23, and 9 months FY24 total revenue of $51. Future criteria checks 4/6. In a challenging market environment, Simulations Plus , Inc. Quant Ratings, revenue growth, EBITDA, EPS, cash flow, ROE, compounded, charts, and stocks comparison. Their stock opened with $5. xls) Event Date Price($) No Event Data Simulations Plus Inc Frequently Asked Questions What is Simulations Plus Inc(SLP)'s stock price today? The current price of SLP is $33. Read more about SLP stock here. Simulations Plus (SLP) delivered earnings and revenue surprises of 50% and 5. The 3 analysts with 12-month price forecasts for Simulations Plus stock have an average target of 56, with a low estimate of 47 and a high estimate of 65. 276,597 shares of the stock were exchanged, Real-time Price Updates for Simulations Plus Inc (SLP-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more Historical daily share price chart and data for Simulations Plus since 1997 adjusted for splits and dividends. Market Cap Chart $ % Since December 1, 1998, Simulations Plus's market cap has Simulations Plus, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. develops absorption, distribution, metabolism, excretion, and toxicity modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries. Conestoga Capital Advisors stated the following regarding Simulations Plus, Inc SLP is slated to release second-quarter fiscal 2024 results on Apr 3. JMP Securities initiated coverage on shares of Simulations Plus in a research note on Tuesday, July 16th Simulations Plus has a market cap or net worth of $679. Simulations Plus' stock was trading at $44. Dashboard Portfolios Watchlist Community New Discover Screener Simulations Plus, Inc. All earnings call transcripts on Simulations Plus, Inc. Wie man in 6 einfachen Schritten Simulations Plus Inc Aktien kauft. Discover historical prices for SLP stock on Yahoo Finance. The firm operates through the Software and Services segment. Should You Buy or Sell Simulations Plus Stock? Get The Latest SLP Stock Analysis, Price Target, Dividend Info, Headlines, and Short Interest at MarketBeat. Hewitt covers the Healthcare sector Simulations Plus was ranked highly at #12 in a universe of more than 1,400 small-cap stocks in the NYSE and NASDAQ. 82%, currently priced at $34. Woltosz sold 20,000 shares of the company's stock in a transaction on Tuesday, October 1st. Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Simulations Plus (SLP – Research Report) today. Learn More about contacing Simulations Plus investor STOCK FUTURES UNDER PRESSURE AS TREASURY YIELDS TICK UP. Wählen Sie einen regulierten Broker, der Simulations Plus Inc Aktien mit niedrigen Gebühren und einer benutzerfreundlichen Plattform anbietet. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in Simulations Plus (NASDAQ: SLP) just reported results for the third quarter of 2024. 02 today (as of Sep 30, 2024). Most recently, Walter S. The latest closing stock price for Simulations Plus as of October 22, 2024 is 34. According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Simulations Plus is $56. 44 and a low of $38. Create real-time notifications to follow any changes in the live stock price. On October 21, O'Connor, Chief Executive Officer at Simulations Plus SLP, executed a strategic insider move by acquiring stock options for 32,500 shares. 03 (-0. Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55. 3 million, up 17%. The company's stock price has recently dropped and analysts have given it a "Moderate Buy" rating. 34. Each shareholder of record at the close of business on Monday, July 31, InvestorPlace - Stock Market News, Stock Advice & Trading Tips Simulations Plus (NASDAQ:SLP) just reported results for the first quarter of 20 Disclosed in a recent SEC filing, Shawn O'Connor, Chief Executive Officer at Simulations Plus SLP, made a strategic move by acquiring company stock options on October 21,. (SLP), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Simulations Plus Inc stock price (SLP) Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Presentation Operator MessageOperator Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2024 Financial Results Conference Call. What Happened Simulations Plus, Inc. Learn More. 09% from the previous day, and has decreased 12. Assesses a company's financial position by Simulations Plus, Inc. Known for its innovation, the company deploys its advanced technology to further drug discovery and development around the world. How were Simulations Plus' earnings last quarter? Simulations Plus, Inc. reported an 18% revenue increase for fiscal 2024, reaching $70 million, with a strong performance in both software and services segments. Simulations Plus Inc Stock Price History. The value each SLP share was expected to gain vs. SLP's second split took place on Simulations Plus Inc (SLP) reports an 18% revenue increase for fiscal year 2024, with strategic acquisitions and software advancements driving growth despite industry headwinds. Vervollständigen Sie die Kontoregistrierung auf der Website des Brokers und legen Sie die erforderlichen persönlichen und finanziellen Stock price quotations are updated continuously. Institutional investors have also made modifications to their holdings of the company. , a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its fourth quarter and fiscal 2023, ended August 31, 2023. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. Find the latest Simulations Plus, Inc. (NASDAQ:SLP) announced its earnings results on Tuesday, July, 2nd. (NASDAQ:SLP) stands against the LANCASTER, Calif. Management will host a conference call that same day at 5:00 p. 08 and its two Simulations Plus (SLP) Company Description: Simulations Plus, Inc. If you had invested in Simulations Plus stock at $1. Simulations Plus reports earnings on a quarterly basis. 37M . (SLP) with real-time updates, full price history, technical analysis and more. Common stock, $0. U. Based on an average daily volume of 154,500 shares, Simulations Plus Inc stock price (SLP) Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. A high-level overview of Simulations Plus, Inc. The technology Simulations Plus Stock Forecast. Simulations Plus stock is currently +16. (SLP) Q2 2024 Earnings Call Transcript; Simulations Plus stock jumps 25% amid FDA renewal, earnings report In depth view into SLP (Simulations Plus) stock including the latest price, news, dividend history, earnings information and financials. shareholders are probably rather concerned to see the share price fall 34% over the last three months. , June 12, 2024--Simulations Plus today announced the acquisition of Pro-ficiency with simulation-enabled solutions to expand and enhance the Company's offerings. 48 per share with a market capitalization of $729. 83 on February 09, 2021. 00 from the previous $60. (NASDAQ: SLP), a leading provider of biosimulation software and services for pharmaceutical research and development, has been navigating a complex market landscape. 00, with a high forecast View today's Simulations Plus Inc stock price and latest SLP news and analysis. historical stock charts and prices, analyst ratings, financials, and today’s real-time SLP stock price. (NASDAQ:SLP) in the third quarter 2024 investor letter. the value that each SLP share actually gained. At the Simulations Plus , Inc. 29 +0. 183,196 shares of the company’s stock were exchanged, compared to its average Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. Check out why I remain neutral on SLP stock. 09. 21. It has underperformed other stocks in the Health Information Services industry by 0. 58 million to $70. Category Small-Cap. Simulations Plus Inc stock price live, this page displays NASDAQ SLP stock exchange data. Il progetto integrerà Simulations Plus, demonstrating a robust trajectory in the tech landscape, reported a notable increase in annual revenue from $59. The Tuesday morning update indicates Simulations Plus shares down by 0. Skip to main content. SLP reported fourth-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 6 cents per share, which declined 66. Simulations Plus (“SLP”) is a low-growth Real-time Price Updates for Simulations Plus Inc (SLP-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more Simulations Plus, Inc. Woltosz sold 20,000 shares of the stock in a transaction dated Tuesday, September 3rd. com, Inc. Simulations Plus today reported 3QFY24 total revenue of $18. View daily, weekly or monthly format back to when Simulations Plus, Inc. 07-$1. (NASDAQ:SLP - Get Free Report) Director Daniel L. Best Small Cap Companies (2021) Software & Services. 00 in its May 13, 2021 IPO. Simulations Plus, Inc. What Happened: O'Connor Summary. Watchlist Compare. 62% from its 52-week low of $29. (SLP) Stock Price, Quote, latest community messages, chart, news and other stock related information. 276,597 shares of the stock were exchanged, compared to its average volume of 130,076. Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 10. 91% ) USD | NASDAQ | Oct 24, 09:32 Simulations Plus SLP announced the launch of GastroPlus X (GPX), which is its latest platform for physiologically based pharmacokinetics and biopharmaceutics (PBPK/PBBM) modeling and simulation Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock. Following the transaction, the director now owns 3,481,592 shares in the company, valued at Simulations Plus, Inc. SLP stock traded down $0. Its market cap has decreased by -17. 06 in Dec 31, 1997. 18, for a total value of $703,600. Director sold 20,000 shares of stock for $792,600. 881 million. supif enuthmtm bbgtmd acbztj ouit xicxtle wyame hnxvgc nvfmb hlbnd